Katherine Jeffery - 14 Jan 2023 Form 4 Insider Report for Pear Therapeutics, Inc. (PEARQ)

Role
Chief People Officer
Signature
/s/ Stacie S. Aarestad, Attorney-in-Fact
Issuer symbol
PEARQ
Transactions as of
14 Jan 2023
Transactions value $
$0
Form type
4
Filing time
18 Jan 2023, 16:01:10 UTC
Previous filing
18 Feb 2022
Next filing
24 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PEARQ Common Stock Options Exercise $0 +15,400 $0 15,400 14 Jan 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PEARQ Restricted Stock Units Options Exercise $0 -15,400 -33% $0 31,267 14 Jan 2023 Common Stock 15,400 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of PEAR common stock.
F2 The remaining restricted stock units shall vest and settle as to 33% of the shares on January 14, 2024 and 34% on January 14, 2025.